Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in multiple myeloma.
MajesTEC-1 Update Shows Tocilizumab to Reduce CRS With Teclistamab in RRMM
Prophylactic treatment with tocilizumab shows promise for reducing a serious adverse effect in multiple myeloma treatment.
Read More
Advancing Myeloma Treatment With Blood-Based MRD Testing
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Listen
IMROZ Trial of Isa-VRd Shows Superior PFS in Transplant-Ineligible Myeloma
The IMROZ trial reveals significant improvements in PFS for patients with newly diagnosed, transplant-ineligible multiple myeloma.
Linvoseltamab, Teclistamab Show Similar Efficacy in R/R Myeloma
Linvoseltamab may have similar — if not better — outcomes compared with teclistamab for patients with triple-class exposed relapsed or refractory multiple myeloma.
Belantamab Offers Similar PROs to Daratumumab Regimen in DREAMM-7 for RRMM
Data from DREAMM-7 showed comparable patient-reported outcomes between belantamab/bortezomib/dexamethasone and daratumumab/bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
Step-Up Teclistamab With Prophylactic Tocilizumab Shows Promise in R/R Multiple Myeloma
A step-up dosing regimen of teclistamab with prophylactic tocilizumab for relapsed/refractory multiple myeloma showed promising responses in a small patient cohort.